Search Results
Results found for "Confo Therapeutics"
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
Despite its therapeutic potential, CB2 pharmacology remains difficult to interrogate with confidence.
- 📰 GPCR Weekly News, April 8 to 14, 2024
Industry News Monash University retains its N° 2 global ranking for Pharmacy and Pharmacology Addex Therapeutics
- 📰 GPCR Weekly News, February 19 to 25, 2024
GPCR Binders, Drugs, and more Advances in structure-based drug design: The potential for precision therapeutics
- 📰 GPCR Weekly News
GPCRs in Neuroscience CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond.
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
crystal structures of both CBRs.[4–8] A key challenge in CBR modulator development is separating the therapeutic New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
have been approved as drugs, however they often have serious side effects and too low or temporary therapeutic Pharmacology & Therapeutics 2016 , 165 , 164–177. https://doi.org/10.1016/j.pharmthera.2016.06.007
- Unlocking Cell's Secrets: Spontaneous β-Arrestin-Membrane Preassociation Drives Receptor-Activation
Pharmacology & therapeutics, 89(2), 139–147. https://doi.org/10.1016/s0163-7258(00)00107-8
- Decoding β-Arrestins: from Structure to function
within distinct cell types or tissues, will undoubtedly provide valuable guidance for advancing such therapeutic
- Structural landscape of the Chemokine Receptor system
binding and receptor activation will pave the way for significant advancements in the development of therapeutics
